IN8bio (INAB)

• Market cap: $9.1M
• 1 day: -6.54%
• 5 days: -14.44%
• 1 month: -35.83%
• 3 months: -41.51%
• 6 months: -53.56%
• Year to date: -62.43%
• 1 year: -56%
• 5 years: -99.68%
• 10 years: -99.69%
• Sector: Healthcare
• Industry: Biotechnology

About: IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Employees: 18